IP Library Granted Patent US 7,300,762
Granted Patent B2
US 7,300,762 · App. 11/251,209 · Granted Nov 27, 2007

Fluorescent proteins and methods of using same

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,300,762
App. No.
11/251,209
Granted
Nov 27, 2007
Kind
B2
Abstract

The present invention provides novel engineered derivatives of green fluorescent protein (GFP) which have an amino acid sequence which is modified by amino acid substitution compared with the amino acid sequence of wild type Green Fluorescent Protein (SEQ ID NO: 2). The modified GFPs exhibit enhanced fluorescence relative to wtGFP when expressed in non-homologous cells at temperatures above 30° C., and when excited at about 490 nm compared to the parent proteins, i.e. wtGFP. An example of a preferred protein is F64L-S175G-E222G-GFP. The modified GFPs provide a means for detecting GFP reporters in mammalian cells at lower levels of expression and/or increased sensitivity relative to wtGFP. This greatly improves the usefulness of fluorescent proteins in studying cellular functions in living cells.

Claims (9)

1. A method of determining the cellular and/or extracellular localisation of a protein of interest comprising:

i) introducing into a cell a nucleic acid molecule comprising a nucleotide sequence encoding a modified Green Fluorescent Protein (GFP) fused to a nucleotide sequence encoding a protein of interest, said nucleic acid molecule being operably linked to and under the control of a suitable expression control sequence;

ii) culturing said cell under conditions suitable for the expression of said protein of interest; and

iii) determining the cellular and/or extracellular localisation of said protein of interest by detecting the fluorescence emission by optical means;

wherein said modified GFP has the amino acid sequence of SEQ ID NO: 2 except for:

a) an amino acid substitution at position F64;

b) a single amino acid substitution at a position selected from the group consisting of positions S65 and E222; and

c) an amino acid substitution at position S175;

wherein said modified GFP has a different excitation spectrum or a different emission spectrum compared with wild type GFP or has a different excitation spectrum and a different emission spectrum compared with wild type GFP.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 31, 2020
From: GE HEALTHCARE UK LIMITED
To: GLOBAL LIFE SCIENCES SOLUTIONS OPERATIONS UK LTD
Reel/Frame 053653/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 18, 2007
From: GE HEALTHCARE LIMITED
To: GE HEALTHCARE UK LIMITED
Reel/Frame 019562/0827 →
CHANGE OF NAME Recorded Oct 21, 2005
From: AMERSHAM PLC
To: GE HEALTHCARE LIMITED
Reel/Frame 016914/0788 →